Cargando…

XIAP underlies apoptosis resistance of renal cell carcinoma cells

X-linked inhibitor of apoptosis (XIAP), a key member of the inhibitors of apoptosis protein family, can inhibit apoptosis by directly binding to the initiator caspase-9, −3 and −7, thereby promoting tumor cell survival during tumor progression. In the present study, XIAP basal expression levels were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wen Zheng, Zhou, Haijiang, Yan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780075/
https://www.ncbi.nlm.nih.gov/pubmed/29115633
http://dx.doi.org/10.3892/mmr.2017.7925
_version_ 1783294674583158784
author Yang, Wen Zheng
Zhou, Haijiang
Yan, Yong
author_facet Yang, Wen Zheng
Zhou, Haijiang
Yan, Yong
author_sort Yang, Wen Zheng
collection PubMed
description X-linked inhibitor of apoptosis (XIAP), a key member of the inhibitors of apoptosis protein family, can inhibit apoptosis by directly binding to the initiator caspase-9, −3 and −7, thereby promoting tumor cell survival during tumor progression. In the present study, XIAP basal expression levels were investigated and its contribution to the resistance to apoptosis was evaluated, in the RCC cell lines exposed to apoptosis-inducing drugs. This was investigated by histological methods and western blot analysis. Using RNA interference, elimination of XIAP in Caki-1 cells was also studied, and its contribution to the sensitivity to apoptosis induced through the intrinsic pathway was observed. Differences in XIAP expression were detected between ClearCa-2 and ClearCa-6 cell lines. ClearCa-6 cells with lower expression of XIAP were more sensitive to apoptosis-inducing drugs, compared with ClearCa-2 cells. However, the levels of XIAP expression in both cell lines were stable during apoptosis. Furthermore, a Caki-1 cell line with no XIAP expression was used, and was demonstrated to be more sensitive to the apoptosis induced by the mitochondrial pathway. These results suggested that downregulation of XIAP expression could enhance the sensitivity of RCC cells to apoptosis, and the basal expression of XIAP during apoptosis is stable. This may provide novel insight for targeted gene therapy against XIAP, in the clinic.
format Online
Article
Text
id pubmed-5780075
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-57800752018-02-12 XIAP underlies apoptosis resistance of renal cell carcinoma cells Yang, Wen Zheng Zhou, Haijiang Yan, Yong Mol Med Rep Articles X-linked inhibitor of apoptosis (XIAP), a key member of the inhibitors of apoptosis protein family, can inhibit apoptosis by directly binding to the initiator caspase-9, −3 and −7, thereby promoting tumor cell survival during tumor progression. In the present study, XIAP basal expression levels were investigated and its contribution to the resistance to apoptosis was evaluated, in the RCC cell lines exposed to apoptosis-inducing drugs. This was investigated by histological methods and western blot analysis. Using RNA interference, elimination of XIAP in Caki-1 cells was also studied, and its contribution to the sensitivity to apoptosis induced through the intrinsic pathway was observed. Differences in XIAP expression were detected between ClearCa-2 and ClearCa-6 cell lines. ClearCa-6 cells with lower expression of XIAP were more sensitive to apoptosis-inducing drugs, compared with ClearCa-2 cells. However, the levels of XIAP expression in both cell lines were stable during apoptosis. Furthermore, a Caki-1 cell line with no XIAP expression was used, and was demonstrated to be more sensitive to the apoptosis induced by the mitochondrial pathway. These results suggested that downregulation of XIAP expression could enhance the sensitivity of RCC cells to apoptosis, and the basal expression of XIAP during apoptosis is stable. This may provide novel insight for targeted gene therapy against XIAP, in the clinic. D.A. Spandidos 2018-01 2017-10-27 /pmc/articles/PMC5780075/ /pubmed/29115633 http://dx.doi.org/10.3892/mmr.2017.7925 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yang, Wen Zheng
Zhou, Haijiang
Yan, Yong
XIAP underlies apoptosis resistance of renal cell carcinoma cells
title XIAP underlies apoptosis resistance of renal cell carcinoma cells
title_full XIAP underlies apoptosis resistance of renal cell carcinoma cells
title_fullStr XIAP underlies apoptosis resistance of renal cell carcinoma cells
title_full_unstemmed XIAP underlies apoptosis resistance of renal cell carcinoma cells
title_short XIAP underlies apoptosis resistance of renal cell carcinoma cells
title_sort xiap underlies apoptosis resistance of renal cell carcinoma cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780075/
https://www.ncbi.nlm.nih.gov/pubmed/29115633
http://dx.doi.org/10.3892/mmr.2017.7925
work_keys_str_mv AT yangwenzheng xiapunderliesapoptosisresistanceofrenalcellcarcinomacells
AT zhouhaijiang xiapunderliesapoptosisresistanceofrenalcellcarcinomacells
AT yanyong xiapunderliesapoptosisresistanceofrenalcellcarcinomacells